Zehua Wu

Dr. Zehua Wu

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JLJianxia Li
Jianxia Li
HHHuabin Hu
Huabin Hu
GQGe Qin
Ge Qin
FBFan Bai
Fan Bai
XWXianrui Wu
Xianrui Wu
YDYanghong Deng
Yanghong Deng
Purpose: Immune checkpoint inhibitors (ICI) have become the standard of care for patients with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) colorectal cancer. However, biomarkers of response to ICI are still lacking. Experimental Design: Forty-two patients with dMMR colorectal cancer treated with neoadjuvant PD-1 blockade were prospectively enrolled. To identify biomarkers of pathologic complete response (pCR) to neoadjuvant therapy, we analyzed genomic and transcriptomic profiles based on next-generation sequencing, and immune cell density based on multiplex immunofluorescence (mIF) staining. An integrated analysis of single-cell RNA sequencing from our previous study and GSE178341, as well as mIF was performed to further explore the significance of the tumor microenvironment (TME) on pCR response. Results: The tumor mutation burden of both tumor tissue and plasma blood samples was comparable between the pCR and non-pCR groups, while HLA-DQA1 and HLA-DQB1 were significantly overexpressed in the pCR group. Gene signature enrichment analysis showed that pathways including T-cell receptor pathway, antigen presentation pathway were significantly enriched in the pCR group. In addition, higher pre-existing CD8+ T-cell density was associated with pCR response (767.47 per.mm2 vs. 326.64 per.mm2, P = 0.013 Wilcoxon test). Further integrated analysis showed that CD8+ T cells with low PD-1 expression (PD-1lo CD8+ T cells) expressing high levels of TRGC2, CD160, and KLRB1 and low levels of proliferated and exhausted genes were significantly associated with pCR response. Conclusions: Immune-associated transcriptomic features, particularly CD8+ T cells were associated with pCR response to ICI in dMMR colorectal cancer. Heterogeneity of TME within dMMR colorectal cancer may help to discriminate patients with complete response to neoadjuvant ICI.

16 January 2023 in Cancers
Verified
Journal Article
Open access
PDF file
ZWZehua Wu
Zehua Wu
YCYi Cheng
Yi Cheng
HWHuaiming Wang
Huaiming Wang
DLDian Liu
Dian Liu
XQXiaoxing Qi
Xiaoxing Qi
YDYanghong Deng
Yanghong Deng
The encouraging effects of HER2-ADC in patients with HER2-low expression cancers indicated the classical classifications based on positive and negative HER2 might no longer be suitable. However, the biology and prognosis of colorectal cancer patients with different HER2 expression status were still not clear. This is a multi-center retrospective study that included patients with histologically confirmed colorectal cancer and determined HER2 status who received radical surgical resection. HER2 immunohistochemistry (IHC) 1+ and IHC 2+ groups were combined and defined as a HER2-low group because of the concordance of clinicopathological characteristics. As compared with the HER2-high group, both the HER2-zero and the HER2-low group had less tumor with perineural invasion (14.3%, 13.1% vs. 31.6%, p = 0.001 and p < 0.001), less stage III disease (41.8%, 39.9% vs. 56.1%, p = 0.044 and p = 0.022), more RAS/BRAF mutation (52.1%, 49.9% vs. 19.5%, p < 0.001 and p < 0.001) and better disease-free survival (DFS) (3y-DFS rate of 78.7%, 82.4% vs. 59.3%, p < 0.001 and p < 0.001). Multivariate analysis and propensity score matching also revealed that HER2-high expression was an independent prognostic factor of DFS. In conclusion, our study revealed that HER2-low colorectal cancer tumors are close to HER2-zero tumors, but different from HER2-high tumors. The routine examination of HER2 IHC is needed in early-stage colorectal cancer.

22 May 2026 in Gut
Verified
Journal Article
Open access
PDF file
RCRunkai Cai
Runkai Cai
WZWeixiang Zhan
Weixiang Zhan
XLXiaoshuang Lyu
Xiaoshuang Lyu
XYXinyi Yang
Xinyi Yang
ZWZehua Wu
Zehua Wu
JZJianwei Zhang
Jianwei Zhang
Background: Immune checkpoint blockade (ICB) has limited efficacy in microsatellite stable (MSS) colorectal cancer (CRC) due to an immunosuppressive tumour microenvironment. Although loss of phosphatase and tensin homologue (PTEN) occurs in 19–36% of MSS CRC cases, its specific role in driving immune exclusion and ICB resistance remains elusive. Objective: To investigate whether PTEN deficiency promotes resistance to ICB in MSS CRC. Design: An integrative analysis of clinical cohort and The Cancer Genome Atlas (TCGA) database was performed to establish the correlation between PTEN expression and therapeutic response. Single-cell RNA sequencing and flow cytometry were used to identify changes in the tumour immune microenvironment. Immunohistochemistry, mass spectrometry, co-immunoprecipitation and confocal microscopy were employed to dissect the non-canonical function of PTEN. Results: PTEN low expression was strongly associated with reduced CD8 + T-cell infiltration and poor survival in patients receiving ICB. Mechanistically, we identified a non-canonical function of PTEN that physically interacts with and stabilises KEAP1 via the C2 domain, shielding KEAP1 from p62-mediated degradation. Consequently, PTEN deficiency promoted KEAP1 degradation and subsequent NRF2 hyperactivation, which transcriptionally upregulated selective-autophagy machinery, thereby driving the selective lysosomal degradation of major histocompatibility complex (MHC)-I. This process abolished CD8 + T-cell recognition and effector functions, resulting in immune evasion. Crucially, pharmacological inhibition of NRF2 with ML385 restored cell surface MHC-I levels and sensitised PTEN-deficient tumours to anti-programmed cell death protein 1 therapy. Conclusions: PTEN deficiency promotes immune evasion in MSS CRC via an NRF2-dependent axis that triggers autophagy-mediated degradation of MHC-I. Targeting NRF2 represents a promising strategy to enhance the efficacy of immunotherapy in PTEN-deficient MSS CRC.

17 January 2024
Verified
Other
Open access
JLJianxia Li
Jianxia Li
HHHuabin Hu
Huabin Hu
GQGe Qin
Ge Qin
FBFan Bai
Fan Bai
XWXianrui Wu
Xianrui Wu
YDYanghong Deng
Yanghong Deng
Purpose:Immune checkpoint inhibitors (ICI) have become the standard of care for patients with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) colorectal cancer. However, biomarkers of response to ICI are still lacking.Experimental Design:Forty-two patients with dMMR colorectal cancer treated with neoadjuvant PD-1 blockade were prospectively enrolled. To identify biomarkers of pathologic complete response (pCR) to neoadjuvant therapy, we analyzed genomic and transcriptomic profiles based on next-generation sequencing, and immune cell density based on multiplex immunofluorescence (mIF) staining. An integrated analysis of single-cell RNA sequencing from our previous study and GSE178341, as well as mIF was performed to further explore the significance of the tumor microenvironment (TME) on pCR response.Results:The tumor mutation burden of both tumor tissue and plasma blood samples was comparable between the pCR and non-pCR groups, while HLA-DQA1 and HLA-DQB1 were significantly overexpressed in the pCR group. Gene signature enrichment analysis showed that pathways including T-cell receptor pathway, antigen presentation pathway were significantly enriched in the pCR group. In addition, higher pre-existing CD8+ T-cell density was associated with pCR response (767.47 per.mm2 vs. 326.64 per.mm2, P = 0.013 Wilcoxon test). Further integrated analysis showed that CD8+ T cells with low PD-1 expression (PD-1lo CD8+ T cells) expressing high levels of TRGC2, CD160, and KLRB1 and low levels of proliferated and exhausted genes were significantly associated with pCR response.Conclusions:Immune-associated transcriptomic features, particularly CD8+ T cells were associated with pCR response to ICI in dMMR colorectal cancer. Heterogeneity of TME within dMMR colorectal cancer may help to discriminate patients with complete response to neoadjuvant ICI.

17 January 2024
Verified
Other
Open access
JLJianxia Li
Jianxia Li
HHHuabin Hu
Huabin Hu
GQGe Qin
Ge Qin
FBFan Bai
Fan Bai
XWXianrui Wu
Xianrui Wu
YDYanghong Deng
Yanghong Deng
Clinical characterization of the cohort and allocation for testing